Here are the 424B prospectus supplements from AXT Inc (AXTI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AXTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AXTI filings page.
AXT, Inc. is offering 8,560,311 shares of common stock pursuant to this prospectus supplement, with a 30-day option to purchase up to 1,284,046 additional shares. The public offering price is $64.25 per share, with estimated gross proceeds of $550.0M before underwriting discounts and expected delivery on or about April 22, 2026, subject to customary closing conditions. Net proceeds are intended to support subsidiary Tongmei’s InP capacity expansion, R&D, working capital and general corporate purposes. The prospectus highlights export-permit risks for indium phosphide substrates from China and notes that permits to ship to the United States are in final stages of review.
AXT, Inc. is offering shares of its common stock under an automatic shelf registration, via a preliminary prospectus supplement dated April 20, 2026, to certain institutional investors. The offering is subject to completion and customary closing conditions.
The company states the net proceeds will be used to support its PRC subsidiary Tongmei’s capacity expansion for indium phosphide substrates for export, for research and development, and for working capital and general corporate purposes. AXT notes all manufacturing is performed in the PRC by its PRC subsidiaries and joint ventures, and it transfers cash within the corporate structure via capital contributions, royalties/fees, transfer-pricing purchases, and dividends.
AXT discloses that Tongmei has obtained export permits for indium phosphide shipments to Europe, Japan, the UK and Canada; U.S. export permits are in final review but not yet issued. The supplement highlights legal and operational risks tied to PRC regulations, export controls including the revised Foreign Trade Law, and cautions that export-permit timing could affect revenue recognition under U.S. GAAP.